Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of PRECAUTIONS

Posaconazole

May 8, 2024

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Posaconazole

Safety measure

PRECAUTIONS should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revised language is underlined.

<table>
<tr><th>Current</th><th>Revision</th></tr>
<tr><td>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)
Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lurasidone hydrochloride, blonanserin, triazolam

10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)
(N/A)</td><td>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)
Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lurasidone hydrochloride, blonanserin, triazolam<u>, rivaroxaban</u>

10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with the following.)
<table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td><u>Rivaroxaban</u></td><td><u>The anticoagulant effect of rivaroxaban may be enhanced, and a risk of haemorrhage may be increased.</u></td><td><u>The plasma concentration of rivaroxaban is expected to rise due to the inhibition of CYP3A4, as well as the possible inhibition of P-gp, by co-administration with posaconazole.</u></td></tr></table></td></tr>
</table>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp